All In Biotech

Drug Trial Radar · NCT05278663

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants

A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Patients

Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Apr 14, 2022

Primary completion

Sep 4, 2023

Study completion Sep 4, 2023

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Mar 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety and tolerability of multiple oral doses of E6742 in participants with systemic lupus erythematosus (SLE).

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • E6742Drug

    E6742 tablet.

  • PlaceboOther

    E6742-matching placebo tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Screening up to 28 days after the last dose of study drug at Day 85 (up to approximately 1 year 5 months)

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Japan

  • Chukyo Hospital

    Nagoya, Aichi-ken, Japan

  • Daido Clinic

    Nagoya, Aichi-ken, Japan

  • Matsuyama Red Cross Hospital

    Matsuyama, Ehime, Japan

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu, Fukuoka, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, Japan

  • St. Luke's International Hospital

    Chuo-ku, Tokyo, Japan

  • Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Tama Medical Center

    Fuchū, Tokyo, Japan

  • Center Hospital of the National Center for Global Health and Medicine

    Shinjuku-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.